{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '(*) These assessments should be performed prior to administration of the IMP (pre-dose).', 'At Visit 1 of each subsequent Treatment Cycle, the conditions for re-treatment will be', 'checked before administration of the IMP (see Section 4.1).', 'Patients may not receive re-treatment with ARGX-113 or placebo if, at the time of re-', 'treatment, patients have clinical evidence of bacterial, viral or fungal disease, or any other', 'significant disease which could confound the results of the trial or put patients at undue risk.', 'Patients who are in need of an additional treatment but who are not eligible to receive re-', 'treatment for reasons listed here will remain in the trial and will be discontinued early from', 'randomized treatment to receive appropriate alternative MG treatment.', 'For the entire duration of the trial, a change in the type or dose/regimen of SoC (replacing,', 'adding or removing SoC, or adjustment of the SoC dose and/or frequency) is not allowed.', '5.4.2.', 'Follow-up Period', 'The FU period within a Treatment Cycle will include weekly assessments starting at Visit 5', 'up to Visit 9 of the corresponding Treatment Cycle.', 'The following assessments will be performed:', 'Efficacy and quality of life assessments should be performed prior to any other trial-', 'specific assessment, except for the weight assessment (if applicable), with the MG-ADL', 'scale to be performed prior to all other efficacy or quality of life assessments (QMG,', 'MGC, EQ-5D-5L and MG-QoL15r).', 'Suicidality assessment.', 'Physical examination.', 'Weight will only be measured in case there is an obvious weight change compared to the', 'last weight assessment.', 'Vital signs.', 'Electrocardiogram.', 'Clinical laboratory tests. Patients need to be fasted at least 8 hours prior to sampling.', 'Urinalysis.', 'Urine pregnancy test (only for women of childbearing potential, see DEFINITION OF', 'TERMS).', 'Pharmacodynamic biomarkers (anti-AChR antibodies in AChR-Ab seropositive patients', 'only, total IgG and subtypes [IgG1, IgG2, IgG3 and IgG4], and anti-MuSK antibodies in', 'MuSK-Ab seropositive patients only).', 'argenx BVBA', 'Confidential', 'Page 67 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Anti-drug antibodies at Visits 6 and 9 from the first Treatment Cycle. As from the', 'second Treatment Cycle onwards, samples for ADA will only be taken at Visit 9 of the', 'corresponding FU period.', 'Pharmacokinetic sampling (only at Visits 5 and 6).', 'Review of concomitant medication and rescue therapy.', 'Assess AEs if any.', '5.5.', 'Inter Treatment Cycle Period', 'The ITC period will consist of visits every 2 weeks, starting 14 days ( 2 days) from the last', 'visit of the previous Treatment Cycle.', 'At each ITCnV, an evaluation of the need for re-treatment should be done. In case the patient', 'is not in need of re-treatment, assessments for ITCnV should be performed as listed below', 'and per general SoA (Table 1). However, in case the evaluation shows that the patient is in', 'need of re-treatment and is also eligible for re-treatment, the assessments according to TC1V1', 'are to be performed instead.', 'The following assessments will be performed:', 'Efficacy and quality of life assessments should be performed prior to any other trial-', 'specific assessment, except for the weight assessment (if applicable), with the MG-ADL', 'scale to be performed prior to all other efficacy or quality of life assessments (QMG,', 'MGC, EQ-5D-5L and MG-QoL15r).', 'Suicidality assessment.', 'Physical examination.', 'Weight will only be measured in case there is an obvious weight change compared to the', 'last weight assessment.', 'Vital signs.', 'Electrocardiogram.', 'Clinical laboratory tests. Patients need to be fasted at least 8 hours prior to sampling.', 'Urinalysis.', 'Urine pregnancy test (only for women of childbearing potential, see DEFINITION OF', 'TERMS).', 'Pharmacodynamic biomarkers (anti-AChR antibodies in AChR-Ab seropositive patients', 'only, total IgG and subtypes [IgG1, IgG2, IgG3 and IgG4], and anti-MuSK antibodies in', 'MuSK-Ab seropositive patients only).', 'argenx BVBA', 'Confidential', 'Page 68 of 110']\n\n###\n\n", "completion": "END"}